Cell Therapeutics, Inc. will acquire Zevalin, the first FDA-approved radioimmunotherapy, from Biogen Idec. CTI will be responsible for marketing, sales, and development of the drug in the U.S. The drug will continue to be sold outside the U.S. by Bayer Schering under a previous agreement with Biogen Idec. Zevalin was approved by the FDA in 2002 to treat patients with relapsed indolent non-Hodgkin’s lymphoma (NHL). In 2006, Biogen Idec reported $16.4 million in Zevalin sales in the U.S. ...